[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Wang E, Lichtenfels R, Bükur J, Ngalame Y, Panelli MC, Seliger B, Marincola FM: Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res; 2004 Oct 15;64(20):7279-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer.
  • We compared the transcriptional profile of primary renal cell cancers (RCCs) with that of normal kidney tissue and several epithelial cancers of nonrenal origin to weigh the contribution that ontogeny and oncogenesis make in molding their genetic profile.
  • Genes responsible for lineage specificity may represent poor molecular targets for immune or drug therapy.
  • Most genes associated with oncogenesis are shared with other cancers and may represent better therapeutic targets.
  • Finally, a small subset of genes is associated with lineage-specific oncogenesis, and these may provide information regarding the biological behavior of RCCs and facilitate diagnostic classification of RCCs.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Carbonic Anhydrases / biosynthesis. Carbonic Anhydrases / genetics. Disease Progression. Gene Expression Profiling. Glutathione Transferase / biosynthesis. Glutathione Transferase / genetics. Humans. Melanoma / genetics. Melanoma / metabolism. Multigene Family. Prognosis. Sarcoma / genetics. Sarcoma / metabolism. Transcription, Genetic

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492247.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


2. Koga F, Kawano K, Honda M, Sumi S, Horimi H, Kondo S, Yoshida K: Sarcomatoid renal cell carcinoma with scant carcinomatous components. Int J Urol; 2000 Feb;7(2):58-60; discussion 61
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid renal cell carcinoma with scant carcinomatous components.
  • At that time a diagnosis of rhabdomyosarcoma of the kidney was made.
  • However, further microscopic examination of another eight sections revealed small areas of clear cell-type renal cell carcinoma (RCC) which transited to sarcomatous components and led to a diagnosis of sarcomatoid RCC.
  • The patient underwent three cycles of adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Sarcoma / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10710249.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  •  go-up   go-down


3. Mensah-Osman EJ, Thomas DG, Tabb MM, Larios JM, Hughes DP, Giordano TJ, Lizyness ML, Rae JM, Blumberg B, Hollenberg PF, Baker LH: Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer; 2007 Mar 1;109(5):957-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.
  • The study investigated the hypothesis that the resistance of osteosarcoma to chemotherapy may be related to the expression of a pregnane xenobiotic receptor (PXR) variant protein and its role as the major inducer of P450 3A4 in these tumors.
  • Real-time PCR and CYP3A catalytic activity using 7-benzyl-trifluoromethyl coumarin (BFC) as the probe substrate were used to measure the induction of P450 3A4 or MDR1. siRNA transfections were performed for PXR and cytotoxicity determined by a colorimetric based assay or Annexin v-Fitc staining.
  • RESULTS: Differences were observed in the molecular size of the PXR protein expressed in sarcoma cell lines when compared with the wildtype PXR expressed in normal liver, kidney, or small intestine.
  • A polyclonal PXR antibody raised against the N-terminus of the wildtype PXR did not detect PXR expressed in these sarcoma cell lines.
  • In the osteosarcoma cell lines, etoposide and doxorubicin were better inducers of P450 3A4 and MDR1 than rifampin. siRNA against PXR down-regulated P450 3A4 expression only in the osteosarcoma cell line.
  • Cytotoxicity assays showed that the resistance of the osteosarcoma cell lines to etoposide correlated with PXR protein expression levels and activation of P450 3A4 and could be prevented by ketoconazole.
  • CONCLUSION: The results suggest that PXR plays a critical role in the regulation of P450 3A4 expression in osteosarcoma and that its expression and activation in these tumors may influence the effect of chemotherapeutic agents on the induction of target genes implicated in drug resistance.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827852110 for PMID:17279585 [PharmGKB] .
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1980 Jul;28(7):700-3 [6156203.001]
  • [Cites] Drug Metab Dispos. 2004 Jan;32(1):149-54 [14709632.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Jul;294(1):387-95 [10871337.001]
  • [Cites] Nature. 2000 Jul 27;406(6794):435-9 [10935643.001]
  • [Cites] Drug Metab Rev. 2000 Aug-Nov;32(3-4):339-61 [11139133.001]
  • [Cites] Biochem J. 2000 Apr 15;347(Pt 2):321-37 [10749660.001]
  • [Cites] Nat Med. 2001 May;7(5):584-90 [11329060.001]
  • [Cites] Drug Metab Dispos. 2001 Nov;29(11):1454-9 [11602521.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):895-902 [11843823.001]
  • [Cites] Mol Pharmacol. 2002 Sep;62(3):439-45 [12181418.001]
  • [Cites] J Pathol. 2003 Feb;199(2):251-8 [12533839.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Feb;304(2):745-52 [12538830.001]
  • [Cites] Biochim Biophys Acta. 2003 Feb 17;1619(3):243-53 [12573484.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):17277-83 [12611900.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4446-54 [12970323.001]
  • [Cites] Oncologist. 2003;8(5):411-24 [14530494.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):43919-27 [12920130.001]
  • [Cites] Drug Metab Dispos. 2004 Sep;32(9):993-1000 [15319341.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2470-5 [14983033.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2047-53 [15026342.001]
  • [Cites] J Pharm Sci. 2004 Aug;93(8):2142-57 [15236461.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):353-66 [3973646.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):126-31 [2491883.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1208-16 [2504890.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):815-20 [7828131.001]
  • [Cites] Nat Med. 1995 Mar;1(3):267-71 [7585045.001]
  • [Cites] Anal Biochem. 1997 May 15;248(1):188-90 [9177742.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S3-8 [9272126.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):572-9 [9344324.001]
  • [Cites] Drug Metab Dispos. 1997 Dec;25(12):1359-69 [9394025.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3195-205 [9784494.001]
  • [Cites] Steroids. 1999 May;64(5):310-9 [10406480.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 5;260(2):377-81 [10403778.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2103-7 [10473093.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):177-86 [15630458.001]
  • [Cites] Essays Biochem. 2004;40:27-39 [15242337.001]
  • [ErratumIn] Cancer. 2013 Mar 1;119(5):1115
  • (PMID = 17279585.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092739-01A1; United States / NCI NIH HHS / CA / R21 CA092739; United States / NCI NIH HHS / CA / R21 CA092739-01A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Steroid; 0 / pregnane X receptor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; VJT6J7R4TR / Rifampin
  • [Other-IDs] NLM/ NIHMS301306; NLM/ PMC3125968
  •  go-up   go-down


Advertisement
4. Jones C, Rodriguez-Pinilla M, Lambros M, Bax D, Messahel B, Vujanic GM, Reis-Filho JS, Pritchard-Jones K: c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours. J Clin Pathol; 2007 Nov;60(11):1226-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunohistochemistry without antigen retrieval for CD117 was carried out on tissue microarrays consisting of 274 Wilms' tumours, 13 clear cell sarcomas of the kidney (CCSK), 10 mesoblastic nephromas (MN), and 7 rhabdoid tumours of the kidney (RTK).
  • RESULTS: Only 8/200 (4.0%) Wilms' tumours exhibited any degree of moderate-strong KIT staining in any of their assessable cell types.
  • This small group of KIT-positive tumours had a shorter time to relapse (p = 0.0044, log-rank test).
  • CONCLUSIONS: KIT overexpression in rare in Wilms' tumours, although does appear to confer a worse prognosis, in particular for patients primarily treated with preoperative chemotherapy.
  • The potential of anti-KIT therapeutic strategies in the treatment of paediatric renal tumours appears to be limited.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Kidney Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Sarcoma, Clear Cell / metabolism. Wilms Tumor / metabolism
  • [MeSH-minor] Antineoplastic Agents. Child. DNA Mutational Analysis. DNA, Neoplasm / genetics. Gene Amplification. Humans. In Situ Hybridization / methods. Neoadjuvant Therapy. Nephrectomy. Prognosis. Survival Analysis. Tissue Array Analysis / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1037-51 [10582338.001]
  • [Cites] Cell Oncol. 2007;29(5):399-408 [17726262.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):486-92 [11914627.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):325-7 [12645332.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):339-45 [12645334.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1293-9 [13679437.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):37-46 [14700607.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):468-73 [14752069.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):463-6 [15113851.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6139-43 [1384954.001]
  • [Cites] Virchows Arch. 1994;424(2):135-41 [7514077.001]
  • [Cites] J Histochem Cytochem. 1994 Nov;42(11):1417-25 [7523489.001]
  • [Cites] Hum Pathol. 1998 May;29(5):498-504 [9596274.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):49-57 [15545668.001]
  • [Cites] Diagn Cytopathol. 2005 Oct;33(4):228-32 [16138375.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):7986-94 [16299227.001]
  • [Cites] Cell Oncol. 2005;27(5-6):319-26 [16373964.001]
  • [Cites] Lab Invest. 2006 Apr;86(4):398-408 [16446704.001]
  • [Cites] J Pathol. 2006 Sep;210(1):49-58 [16823893.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11148-55 [17145858.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):4-18 [10632483.001]
  • (PMID = 17965221.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 11886
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2095465
  •  go-up   go-down


5. Iankelevich MIa, Dolgopolov IS, Andreeva LIu, Ravshanova RS, Izhogin DG, Mkheidze DM, Ogorodnikova EV, Mentkevich GL: [Use of subgrafting doses of peripheral stem cells is a new approach to overcoming hematological toxicity of multiple intensive courses of chemotherapy in children]. Vestn Ross Akad Med Nauk; 2000;(6):21-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of subgrafting doses of peripheral stem cells is a new approach to overcoming hematological toxicity of multiple intensive courses of chemotherapy in children].
  • The authors examined 8 patients with pretreated relapsing or resistant solid tumors (Wilms'--4, rhabdomyosarcoma--3, synovial sarcoma--1) who received 16 courses of chemotherapy: iphosphamide, 1800 mg/m2/day (days 1-5), vepeside, 100 mg/m2/day (days 1-5), and carboplatin 500 mg/m2/day (day 1) (IVC) and 18 courses of therapy wherein iphosphamide was replaced by cyclophosphanum, 400 mg/m2/day (days 1-5) (CVC).
  • The findings suggest that the small doses of PSC stimulated by colony-stimulating factor can maintain hemopoiesis and decrease the rate of the estimated bone marrow depletion long after repeated courses of chemotherapy in patients with prognostically poor solid tumors.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10943156.001).
  • [ISSN] 0869-6047
  • [Journal-full-title] Vestnik Rossiiskoi akademii meditsinskikh nauk
  • [ISO-abbreviation] Vestn. Akad. Med. Nauk SSSR
  • [Language] RUS
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


6. Yuan R, Kay A, Berg WJ, Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol; 2009 Oct 27;2:45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
  • Consequently, inhibitors of mTOR, including temsirolimus, everolimus, and ridaforolimus (formerly deforolimus) have been developed and assessed for their safety and efficacy in patients with cancer.
  • Temsirolimus is an intravenously administered agent approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of advanced renal cell carcinoma (RCC).
  • Everolimus is an oral agent that has recently obtained US FDA and EMEA approval for the treatment of advanced RCC after failure of treatment with sunitinib or sorafenib.
  • The use of mTOR inhibitors, either alone or in combination with other anticancer agents, has the potential to provide anticancer activity in numerous tumor types.
  • Cancer types in which these agents are under evaluation include neuroendocrine tumors, breast cancer, leukemia, lymphoma, hepatocellular carcinoma, gastric cancer, pancreatic cancer, sarcoma, endometrial cancer, and non-small-cell lung cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cell Transformation, Neoplastic / drug effects. Drug Delivery Systems / methods. Drug Discovery. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Neoplasms / drug therapy. Protein-Serine-Threonine Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1588-95 [18332470.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2756-62 [18451242.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1596-602 [18332467.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):508-14 [18543327.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4311-8 [18779618.001]
  • [Cites] BJU Int. 2009 Mar;103(5):572-7 [19154471.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(5):765-73 [19157861.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2438-46 [19306412.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2630-7 [19380449.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Ann Oncol. 2009 Oct;20(10):1674-81 [19549709.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):69-76 [19933912.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1904-10 [20231677.001]
  • [Cites] Cancer. 2010 Dec 1;116(23):5415-9 [20681032.001]
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):33085-91 [10551878.001]
  • [Cites] Gut. 2000 Aug;47(2):272-6 [10896921.001]
  • [Cites] Breast Cancer Res. 2000;2(5):335-44 [11250726.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):289-96 [11773181.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Dec;66(4):579-91, table of contents [12456783.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):420-4 [12853790.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):847-58 [12944570.001]
  • [Cites] Trends Biochem Sci. 2003 Nov;28(11):573-6 [14607085.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5078-84 [14613984.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7652-6 [14633685.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2336-47 [15136596.001]
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] Expert Opin Emerg Drugs. 2007 Nov;12(4):605-18 [17979602.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):84-91 [18039566.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):361-7 [18202410.001]
  • [Cites] Mod Pathol. 2008 Mar;21(3):231-7 [18157089.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1576-8 [18332465.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1603-10 [18332469.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2954-63 [15254063.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1510-6 [15367412.001]
  • [Cites] J Antibiot (Tokyo). 1975 Oct;28(10):727-32 [1102509.001]
  • [Cites] Cancer Treat Rev. 1981 Mar;8(1):63-87 [7248995.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3581-7 [10446965.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):931-7 [15539386.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4991-5004 [15611513.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2047-53 [15781610.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):127-44 [16139957.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2028-37 [16489002.001]
  • [Cites] Nephrol Dial Transplant. 2006 Jul;21 Suppl 3:iii18-23 [16815852.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5755-63 [17020981.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1148-54 [17031397.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1777-82 [17003820.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7215-20 [17189392.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24 [17259554.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):163-72 [17382271.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):599-605 [17577220.001]
  • [Cites] Pathology. 2007 Oct;39(5):482-5 [17886097.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Nov;64(2):115-28 [17702596.001]
  • (PMID = 19860903.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Intracellular Signaling Peptides and Proteins; 0 / Protein Kinase Inhibitors; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 103
  • [Other-IDs] NLM/ PMC2775749
  •  go-up   go-down


7. Ohgaki K, Horiuchi K, Mizutani S, Sato M, Kondo Y: Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney that responded to low-dose chemotherapy with ifosfamide, etoposide, and doxorubicin. Int J Clin Oncol; 2010 Apr;15(2):210-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney that responded to low-dose chemotherapy with ifosfamide, etoposide, and doxorubicin.
  • A primitive neuroectodermal tumor (PNET) is a small round cell tumor that arises from the nerve crest.
  • This tumor usually occurs in the central nervous system or soft tissue, but it can occur in the kidney in rare cases.
  • Some of the cells formed a rosette structure and the tumor cells were positive for CD99, leading to diagnosis of PNET.
  • Severe multiple liver metastases occurred 6 months after surgery, and six courses of chemotherapy with ifosfamide, etoposide and doxorubicin were performed.
  • After this treatment, residual tumor was removed, but the tumor cells were absent histologically.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / surgery. Liver Neoplasms / drug therapy. Nephrectomy. Neuroectodermal Tumors, Primitive / drug therapy. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Biopsy. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):354-9 [9060607.001]
  • [Cites] BJU Int. 2003 Jan;91(1):121-2 [12614265.001]
  • [Cites] Int Urol Nephrol. 2001;33(3):449-51 [12230269.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):133-46 [11176062.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):320-7 [11859203.001]
  • [Cites] Urology. 2008 Feb;71(2):292-6 [18308106.001]
  • [Cites] Urology. 1994 Jul;44(1):127-9 [8042253.001]
  • [Cites] Pathol Int. 2000 Dec;50(12 ):967-72 [11123763.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Scand J Urol Nephrol. 2007;41(1):75-6 [17366107.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):264-8 [15085765.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1191-8 [3114435.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1999 Jun;90(6):639-42 [10422440.001]
  • [Cites] Pathol Res Pract. 2001;197(2):113-119; discussion 121-2 [11261815.001]
  • [Cites] Intern Med. 2004 Jul;43(7):578-81 [15335184.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):767-71 [9224742.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):767-75 [17238190.001]
  • [Cites] Lung Cancer. 2000 Jan;27(1):55-60 [10672784.001]
  • [Cites] Perspect Pediatr Pathol. 1975;2:151-72 [1129029.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2008 Mar;99(3):560-4 [18404886.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2243-50 [9179073.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):180-3 [16544300.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1825-9 [1848468.001]
  • [Cites] BMC Cancer. 2004 Jan 26;4:3 [14969593.001]
  • (PMID = 20186557.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


8. Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, Hawkins MJ: A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res; 2000 Apr;6(4):1259-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
  • GEM231 is a mixed-backbone oligonucleotide targeting the regulatory subunit alpha of type I protein kinase A, which plays an important role in growth and maintenance of malignancies.
  • Tumor histologies included non-small cell lung cancer, renal cell cancer, sarcoma, and others.
  • There was no treatment-related complement activation or thrombocytopenia at any dose level, except with the first dose in one patient who had pre-existing borderline thrombocytopenia.
  • Transient activated partial thrombin time prolongation occurred at doses > or =160 mg/m2.
  • Dose-limiting toxicities included transient activated partial thrombin time prolongation (one of three patients at 360 mg/m2) and cumulative reversible transaminase elevation (three of three patients at 360 mg/m2 and three of six patients at 240 mg/m2 during weeks 3-10).
  • Thus, in this first clinical evaluation of a mixed-backbone oligonucleotide in cancer patients, high plasma concentrations of GEM231 were well tolerated without significant acute toxicities, but prolonged treatment was associated with reversible transaminitis.
  • Although 240 mg/m2 by 2-h infusion twice weekly was safe for a 4-week treatment duration, alternative dosing schedules are being tested to minimize the cumulative toxicity, which will be essential to extend the duration of therapy at the highest GEM231 dose tested.
  • [MeSH-major] Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors. Neoplasms / drug therapy. Oligonucleotides, Antisense / pharmacokinetics
  • [MeSH-minor] Aged. Alanine Transaminase / blood. Alanine Transaminase / drug effects. Area Under Curve. Base Sequence. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / metabolism. Cyclic AMP-Dependent Protein Kinase RIalpha Subunit. Diarrhea / chemically induced. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Humans. Infusions, Intravenous. Kidney Neoplasms / drug therapy. Kidney Neoplasms / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Male. Metabolic Clearance Rate. Middle Aged. Partial Thromboplastin Time. Sarcoma / drug therapy. Sarcoma / metabolism. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10778949.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / Oligonucleotides, Antisense; 0 / PRKAR1A protein, human; EC 2.6.1.2 / Alanine Transaminase; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  •  go-up   go-down


9. Romero-Rojas AE, Díaz-Pérez JA, Messa-Botero OA, Neira-Mejia FE: Early age renal synovial sarcoma. Arch Esp Urol; 2010 Jul-Aug;63(6):464-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early age renal synovial sarcoma.
  • OBJECTIVE: We report a primary renal Synovial Sarcoma (SS) case and analyze its features.
  • CT scan images showed a 13 cm mass located in the lower pole of the left kidney.
  • Chemotherapy and radical nephrectomy were carried out.
  • RESULTS: The final immunohistochemistry studies gave the diagnosis of poorly differentiated renal SS small cell variety.
  • These tumors, when located in the kidney, represent a great diagnostic challenge that requires adequate clinical, radiological, surgical, and pathological correlation for appropriate diagnosis and treatment.
  • [MeSH-major] Kidney Neoplasms. Sarcoma, Synovial

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20820086.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


10. Maeda M, Tsuda A, Yamanishi S, Uchikoba Y, Fukunaga Y, Okita H, Hata J: Ewing sarcoma/primitive neuroectodermal tumor of the kidney in a child. Pediatr Blood Cancer; 2008 Jan;50(1):180-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing sarcoma/primitive neuroectodermal tumor of the kidney in a child.
  • Computed tomography scan confirmed a large right renal mass with necrosis.
  • Based on small round cell histology, strong MIC-2 (CD99) positive tumor cells, and EWS-FLI-1 fusion transcript, Ewing sarcoma/primitive neuroectodermal tumor of the kidney was diagnosed.
  • Induction and follow-up with seven cycles of chemotherapy were given after surgery.
  • She has had no evidence of recurrence 90 months from diagnosis.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Neuroectodermal Tumors, Primitive, Peripheral / diagnosis. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16544300.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Davidson A, Dick G, Pritchard-Jones K, Pinkerton R: EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation. Eur J Cancer; 2002 Dec;38(18):2422-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
  • Tumour types were neuroblastoma 3, Ewing's sarcoma 2, rhabdomyosarcoma 5, osteosarcoma 3, desmoplastic small round cell tumour 1, nephroblastoma 1, T-acute lymphoblastic leukaemia (ALL) 1.
  • All had progressed or relapsed following at least two of the drug types included in EVE.
  • Partial responses (PR) were observed in 2 patients (1 rhabdomyosarcoma, 1 Ewing's sarcoma).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclosporine / administration & dosage. Cyclosporine / adverse effects. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gastrointestinal Diseases / chemically induced. Heart Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Kidney Diseases / chemically induced. Male. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2002 Dec;38(18):2337-40 [12460776.001]
  • (PMID = 12460787.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


12. Kountourakis P, Kandylis K, Daskalopoulou D, Rigatos G: Sarcomatoid differentiation of renal cell carcinoma: a clinical case with literature review. J BUON; 2008 Apr-Jun;13(2):281-3
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid differentiation of renal cell carcinoma: a clinical case with literature review.
  • A small percentage (1-10%) of renal cell carcinomas (RCC) belongs to the sarcomatoid variant.
  • These malignancies are aggressive with worse prognosis and unfortunately the results following immuno- and/or chemotherapy administration are discouraging.
  • A 62-year-old Caucasian male with advanced renal cell cancer and sarcomatoid component treated with sunitinib is presented.
  • Better understanding of prognostic and molecular markers might help the selection of patients with a chance of benefiting from administration of new targeted drugs.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Cell Differentiation. Kidney Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Fatal Outcome. Humans. Indoles / therapeutic use. Male. Middle Aged. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555479.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


13. Stehr M, Deilmann K, Haas RJ, Dietz HG: Surgical complications in the treatment of Wilms' tumor. Eur J Pediatr Surg; 2005 Dec;15(6):414-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical complications in the treatment of Wilms' tumor.
  • We present our data on the treatment of Wilms' Tumor (WT) with an emphasis on both the positive effect and the adverse effect of preoperative chemotherapy with regard to surgical intervention.
  • 57 % received preoperative chemotherapy (ChTx) and 43 % were operated on primarily.
  • In 8 % of the patients with preoperative chemotherapy intraoperative complications occurred with a rupture of the tumor in 1 case.
  • 1 child (1.5 %) was treated with chemotherapy who did not have a Wilms' tumor but a benign nephroma (CMN).
  • 3 cases had a clear cell sarcoma (CCSK) and in one case histology revealed a rhabdoid tumor (MRTK).
  • In one case of CCSK only histology of the metastases disclosed the correct diagnosis.
  • Irrespective of the known adverse effects such as changing tumor histology, which may affect the correct staging, and the remaining risk of an initial inadequate treatment, our data show that the regimen of preoperative chemotherapy as proposed by the SIOP study should not be abandoned.
  • However, the relatively small number of our patients does not allow a significant statement to be made but confirms the results of past SIOP studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intraoperative Complications. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Nephrectomy. Wilms Tumor / drug therapy. Wilms Tumor / surgery
  • [MeSH-minor] Child, Preschool. Dactinomycin / administration & dosage. Humans. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418959.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine
  •  go-up   go-down


14. Grundy RG, Hutton C, Middleton H, Imeson J, Pritchard J, Kelsey A, Marsden HB, Vujanic GM, Taylor RE, United Kingdom Children's Cancer Study Group: Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2); a United Kingdom Children's Cancer Study Group (UKCCSG) study. Pediatr Blood Cancer; 2004 Apr;42(4):311-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: The second UK WT trial (UKWT2) ran between July 1986 and September 1991 accruing 448 patients.
  • Six had clear cell sarcoma of the kidney (CCSK) and seven had rhabdoid tumours of the kidney (RTK) and are analysed separately.
  • Seventy-five received standard chemotherapy and abdominal radiotherapy according to protocol.
  • Thirty-three patients had inoperable disease at diagnosis and received pre-nephrectomy chemotherapy.
  • The combination of abdominal RT together with 3-drug chemotherapy achieves a high abdominal tumour control rate.
  • The high cure rates for children in this trial with 'inoperable disease' suggests that treatment should be modified according to their post-chemotherapy stage in order to avoid over-treatment.
  • The high OS for stage III CCSK on this protocol suggests that treatment duration could be curtailed and the role of RT reviewed, though the numbers are small.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Child. Dactinomycin / therapeutic use. Doxorubicin / therapeutic use. Great Britain. Humans. Radiotherapy, Adjuvant. Sarcoma, Clear Cell / drug therapy. Sarcoma, Clear Cell / mortality. Sarcoma, Clear Cell / radiotherapy. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14966826.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down


15. Ferrucci PF, Martinoni A, Cocorocchio E, Civelli M, Cinieri S, Cardinale D, Peccatori FA, Lamantia G, Agazzi A, Corsini C, Tealdo F, Fiorentini C, Cipolla CM, Martinelli G: Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Transplant; 2000 Jan;25(2):173-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy.
  • Peripheral blood progenitor cell reinfusion (PBPC) in patients undergoing high-dose chemotherapy (HDC) for poor prognosis malignancies, has been described as causing possible acute gastrointestinal (nausea, vomiting), allergic (oedema, bronchospasm, anaphyl- axis), renal (proteinuria, haematuria) and/or cardiovascular (hypotension, arrhythmia, conduction disturbances, transient ischaemic phenomena) toxicities.
  • To establish the clinical relevance of these observations and the possible relationship with different HDC regimens used, we performed a clinical and instrumental evaluation on 33 patients with advanced breast cancer, non-Hodgkin's lymphoma, Hodgkin's disease, relapsed ovarian cancer, Ewing's sarcoma, extragonadal germinal tumour and small cell lung cancer.
  • To evaluate cardiovascular function, we continuously monitored 12-lead ECGs, with arterial pressure (AP) measurements every 5 min from the beginning of the procedure to 15 min after the reinfusion ended.
  • We did not observe any significant differences between basal and subsequent steps in AP, heart rate, PQ and QTc time, P wave and QRS complex duration or P wave and QRS electrical axes.
  • No patient showed any ST-T tract pathological abnormality, but one patient developed a transient ectopic atrial rhythm, without any haemodynamic disfunction and with spontaneous reversion to sinus rhythm.
  • In one patient a tonic-clonic seizure occurred during a vomiting episode, but no patient developed allergic or renal toxicities.
  • We conclude that PBPC reinfusion, if managed according to the procedure we propose in patients without organic impairment, is a safe procedure not associated either with increased risk of acute arrhythmias or ischaemic or significant systemic acute toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasms / therapy
  • [MeSH-minor] Adult. Blood Transfusion, Autologous / adverse effects. Cardiovascular Diseases / etiology. Cardiovascular Diseases / physiopathology. Catheterization, Central Venous. Electrocardiography. Female. Gastrointestinal Diseases / etiology. Hemodynamics. Humans. Kidney Diseases / etiology. Leukapheresis. Male. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Bone Marrow Transplant. 2002 Mar;29(6):544 [11960281.001]
  • (PMID = 10673676.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


16. LaPlant KD, Louzon PD: Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Ann Pharmacother; 2010 Jun;44(6):1054-60
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
  • OBJECTIVE: To summarize the currently available clinical data on pazopanib, as well as review the merits and adverse effects of pazopanib in the treatment of renal cell carcinoma (RCC).
  • Phase 2 and 3 studies have shown promising activity in RCC, including treatment naïve or cytokine-pretreated patients, demonstrating a greater rate of total disease control with pazopanib compared to placebo.
  • Activity has also been shown in a variety of other cancers, including ovarian cancer, non-small-cell lung cancer, breast cancer, and soft tissue sarcoma.
  • Other Phase 3 trials are ongoing in RCC, including a comparison to sunitinib, another TKI used in RCC, as well as trials in other tumor types.
  • CONCLUSIONS: Current data suggest pazopanib to be a viable treatment option as first-line therapy for advanced RCC.
  • Until results of head-to-head trials conducted of the various agents are available, it cannot be said whether pazopanib is more tolerable or efficacious than currently available therapies.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Drug Delivery Systems / methods. Kidney Neoplasms / drug therapy. Protein Kinase Inhibitors / administration & dosage. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / administration & dosage. Sulfonamides / administration & dosage

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407031.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 36
  •  go-up   go-down


17. Poprach A, Michalová E, Pavlík T, Lakomy R, Vyskocil J, Nemeccek R, Zaloudík J, Vyzula R, Kocák I, Kocáková I: [Actual state of ex vivo chemoresistance testing of malignant tumors in Masaryk Memorial Cancer Institute Brno]. Klin Onkol; 2008;21(3):116-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemoresistance assay results may play a role in cancer management decision process.
  • Five groups of different types of cancer in particular clinical stages were defined for chemosensitivity testing with:.
  • (1) metastatic malignant melanoma, (2) soft tissue sarcoma (STS), either primary or recurrent/metastic, (3) primary or metastatic renal cancer, (4) recurrent ovarian cancer and (5) other diagnosis "on clinician's request".
  • Sensitivity to certain chemotherapy agent observed ex vivo does not necessarily mean that the cancer would also be sensitive to the same agent in vivo, however, ex vivo resistance with following in vivo sensitivity of the tumour has not been observed to date.
  • The cultivation of malignant cells is very uncertain in solid tumours, which consist of several malignant cell multiclones (benign/stromal cells may outgrow malignant cells).
  • The small number of successfully evaluated samples has not yet provided us to carry out proper statistical evaluation and clinical application.
  • [MeSH-major] Drug Screening Assays, Antitumor
  • [MeSH-minor] Drug Resistance, Neoplasm. Female. Humans. Kidney Neoplasms / drug therapy. Melanoma / drug therapy. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097421.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


18. Skotnicka-Klonowicz G, Bagłaj M, Sawicz-Birkowska K, Balcerska A, Dembowska B, Szymik-Kantorowicz S, Madziara W: [Nephroblastoma in children aged less than 6 months at diagnosis]. Med Wieku Rozwoj; 2003 Jul-Sep;7(3):347-57
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephroblastoma in children aged less than 6 months at diagnosis].
  • We present the results of treatment of kidney tumours in newborns and infants aged less than 6 months, in the years 1993-2000, from the Nephroblastoma Committee of the Polish Paediatric Group of Solid Tumours (PPGGL).
  • We have analysed the diagnostic and treatment results in the group of 31 children aged 0 to 6 months.
  • Among 450 children registered between 1993 and 2000 by PPGGL and treated for kidney tumours, there were 31 (7.1%) newborns and infants aged below 6 months.
  • The accuracy of diagnosis based on imaging studies was 97%.
  • Only in one child the initial diagnosis of kidney tumour was not confirmed; cystic degeneration of kidney was finally established.
  • The tumours removed during surgery were small, with average size 213 cm3, and in half of the cases the size of the tumour did not exceed 165 cm3.
  • In 10 cases histopathology confirmed mesoblastic nephroma, in 19 cases nephroblastoma and in 2 cases sarcoma clarocellulare.
  • In 10 infants (32.2%) with nephroblastoma delayed surgery preceded by chemotherapy was performed.
  • Indications for initial preoperative chemotherapy comprised: tumour in a single kidney, tumour in a horseshoe kidney, preoperative diagnostic biopsy of the tumour and large tumour in neonates older than 3 months.
  • The tolerance of reduced chemotherapy by the infants was good. AS was 100%.
  • ESF for the 19 children registered for nephroblastoma between 1993 and 1996 for all stages of advancement and types of histology was 94.75%.
  • 2) The results of treatment of nephroblastoma in the youngest children (below 6 months of age) are the most favourable and represent world standards.3) Surgical complications in children operated primarily for nephroblastoma indicate the need of performing such operations in academic centres, specialised in newborn surgery.
  • 4) In infants with extensive kidney tumours older than 3 months, primarily considered as inoperative, individual induction chemotherapy should be taken into account.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Wilms Tumor / diagnosis. Wilms Tumor / therapy
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Nephroma, Mesoblastic / diagnosis. Nephroma, Mesoblastic / therapy. Poland. Retrospective Studies. Sarcoma, Clear Cell / diagnosis. Sarcoma, Clear Cell / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14963342.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


19. Ammani A, Ghadouane M, Hajji F, Janane A, Ameur A, Abbar M: [Primitive neuroectodermal tumor (PNET) of the upper-urinary tract]. Prog Urol; 2009 Sep;19(8):579-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primitive neuroectodermal tumors (PNETs) are rare and aggressive malignant small round cell sarcomas.
  • Primitive urogenital location of PNETs is rare and occurs most frequently in the kidney.
  • Its diagnosis is almost postoperative within pathological study of the operatory specimen, supported by immunohistochemistry and cytogenetics.
  • Treatment is similar in all to that of Ewing's sarcoma and involves surgery, chemotherapy and radiotherapy.
  • We report a new case of upper-urinary tract PNET and discuss the diagnostic and therapeutic problems posed by this particular tumor.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19699458.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI).
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Frequently this includes adjacent organs such as colon, small bowel, kidney, adrenal, and pancreas.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


21. Vujanić GM, Kelsey A, Mitchell C, Shannon RS, Gornall P: The role of biopsy in the diagnosis of renal tumors of childhood: Results of the UKCCSG Wilms tumor study 3. Med Pediatr Oncol; 2003 Jan;40(1):18-22
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of biopsy in the diagnosis of renal tumors of childhood: Results of the UKCCSG Wilms tumor study 3.
  • BACKGROUND: The United Kingdom Children's Cancer Study Group (UKCCSG) Wilms Tumor Study 3 has adopted preoperative chemotherapy for Wilms tumors (WT), but required prechemotherapy biopsy for histologic diagnosis.
  • The aims of this review were to assess the usefulness and safety of prechemotherapy biopsy and to compare histologic features of WT before and after chemotherapy.
  • PROCEDURE: There were 286 eligible patients but only 241 biopsies and 226 nephrectomy case slides were submitted for panel review.
  • The presence of different histologic components of WT before and after chemo therapy was retrospectively assessed.
  • One child required emergency nephrectomy due to massive intratumoral bleeding, another had tumor rupture and subsequently died, and a third developed a needle track recurrence 8 months after the biopsy.
  • CONCLUSIONS: A number of renal tumors (12%) can have the correct histologic diagnosis made by PCNB.
  • Preoperative chemo therapy markedly decrease in the number of samples with preserved blastema.
  • The morbidity associated with PCNB is small.
  • Needle biopsy of any renal mass prior to initiation of chemotherapy is recommended.
  • [MeSH-major] Biopsy, Needle. Kidney Neoplasms / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Carcinoma, Renal Cell / pathology. Child. Female. Great Britain. Humans. Male. Nephrectomy. Neuroblastoma / pathology. Predictive Value of Tests. Retrospective Studies. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology. Sensitivity and Specificity. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12426681.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Maity P, Chakraborty S, Bhattacharya P: A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase. J Exp Clin Cancer Res; 2000 Jun;19(2):161-4
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase.
  • Distribution of glutamine level in different tissues of tumor bearing mice such as brain, liver, kidney, spleen, large and small intestine and the tumor itself were studied in three solid tumor models, viz, Ehrlich ascites carcinoma, Sarcoma-180 and methylcholanthrene induced carcinoma.
  • Tumor bearing mice were subjected to therapy for 7 days with the glutaminase purified from malignant S-180 cell.
  • The results exhibit a significant decrease in tumor burden after enzyme therapy.
  • Host tissue glutamine levels were significantly elevated in tumor bearing untreated mice in comparison to the normal ones, while significant lower values were obtained after enzyme therapy.
  • It therefore appears that elevated levels of glutamine in host tissue are associated with the tumor burden.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Glutaminase / therapeutic use. Glutamine / metabolism. Sarcoma 180 / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Brain / metabolism. Intestines / metabolism. Kidney / metabolism. Liver / metabolism. Male. Methylcholanthrene / toxicity. Mice. Spleen / metabolism. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965812.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0RH81L854J / Glutamine; 56-49-5 / Methylcholanthrene; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down


23. Hensley ML, Dizon D, Derosa F, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Colevas AD, Spriggs D, Aghajanian C: A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs; 2007 Aug;25(4):335-41
Hazardous Substances Data Bank. Ixabepilone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dose-limiting toxicity definitions were based on severe myelosuppression, or grade 3 or 4 treatment-related non-hematologic toxicity, or dose delay of greater than 2 weeks due to treatment toxicity observed in the first treatment cycle.
  • Treatment-related toxicities included neutropenia, thrombocytopenia, neutropenic fever, hypophosphatemia, and hyponatremia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carcinoma, Small Cell / drug therapy. Cohort Studies. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Epothilones / administration & dosage. Female. Humans. Kidney Neoplasms / drug therapy. Leukopenia / chemically induced. Lung Neoplasms / drug therapy. Male. Melanoma / drug therapy. Middle Aged. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Urinary Bladder Neoplasms / drug therapy. Uterine Neoplasms / drug therapy. Water-Electrolyte Imbalance / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8724-9 [16314632.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1439-46 [15735119.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(2):169-70 [12701971.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1082-8 [17261851.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):314-9 [14751176.001]
  • [Cites] J Antibiot (Tokyo). 1996 Jun;49(6):560-3 [8698639.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15 [8893876.001]
  • [Cites] Anticancer Drugs. 2004 Jul;15(6):553-8 [15205596.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2325-33 [7757983.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):593-6 [13678730.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2534-41 [8999970.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Invest New Drugs. 2006 Nov;24(6):515-20 [16699973.001]
  • (PMID = 17364235.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01-CA69856
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epothilones; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; K27005NP0A / ixabepilone
  •  go-up   go-down


24. Strumberg D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc); 2005 Dec;41(12):773-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
  • Tumor survival, growth and metastasis depend on efficient tumor cell proliferation and tumor angiogenesis, and targeting both of these processes simultaneously could prove to be therapeutically relevant.
  • The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation, and angiogenesis and is often aberrantly activated in human tumors due to the presence of activated Ras or mutant B-Raf, or elevation of growth factor receptors.
  • Sorafenib, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable kinase selectivity profile.
  • Further characterization showed that sorafenib suppresses both wild-type and V599E mutant B-Raf activity in vitro.
  • Preclinically, sorafenib showed broad-spectrum antitumor activity in colon, breast and non-small-cell lung cancer xenograft models.
  • A total of four phase I studies using oral sorafenib as a single agent have been completed, and the compound showed a favorable safety profile with mild to moderate diarrhea being the most common treatment-related adverse event.
  • Single-agent phase II trials reported so far demonstrated antitumor activity of sorafenib in patients with hepatocellular carcinoma, sarcoma and renal cell cancer (RCC).
  • Food and Drug Administration for this indication is pending.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Pyridines / therapeutic use
  • [MeSH-minor] Administration, Oral. Animals. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Renal Cell / drug therapy. Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / therapeutic use. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Prous Science
  • (PMID = 16474853.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 78
  •  go-up   go-down






Advertisement